Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

SAWAI GROUP expects positive quarter: analysts see sharply improved EPS

SAWAI GROUP will release results for the quarter ended March 31, 2026 on May 15, 2026. Three analysts forecast an average earnings per share of 27.90 JPY versus -115.73 JPY a year earlier, and five analysts see revenue at about 49.88 billion JPY (+8.87% vs 45.82 billion JPY). For the past fiscal year, nine analysts project EPS of 119.45 JPY (previously 96.54 JPY) and revenue of 203.54 billion JPY (previously 189.02 billion JPY). » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Sawai Group Holdings has already paid €0.15 in dividends. The last payout was in June.

Financials

In the last quarter, Sawai Group Holdings had revenue of €342.45m and net profit of €16.12m

(EUR)	June 2026	YoY
Revenue	342.45m	17.24%
Gross profit	100.01m	9.82%
Net profit	16.12m	44.13%
EBITDA	33.71m	47.91%

Fundamentals

Metric	Value
Market capitalization	€1.12bn
Number of shares	115.49m
52-week high/low	€13.89 - €8.80
Dividend yield	0.88%
Dividends TTM	€0.30
Beta	0.03
P/E ratio	22.72
PEG ratio	0.52
P/B ratio	0.89
P/S ratio	0.92

Company profile

Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company's products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.